Display options
Cite
Carneiro BA, Collier KA, Nagy RJ, et al. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in . JCO Precis Oncol. 2018;2doi: 10.1200/PO.17.00176.
Carneiro, B. A., Collier, K. A., Nagy, R. J., Pamarthy, S., Sagar, V., Fairclough, S., Odegaard, J., Lanman, R. B., Costa, R., Taxter, T., Kuzel, T. M., Fan, A., Chae, Y. K., Cristofanilli, M., Hussain, M. H., Abdulkadir, S. A., Giles, F. J., Crawford, R., & Jenkins, L. (2018). Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in . JCO precision oncology, 2. https://doi.org/10.1200/PO.17.00176
Carneiro, B A, et al. "Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in ." JCO precision oncology vol. 2 (2018). doi: https://doi.org/10.1200/PO.17.00176
Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ, Crawford R, Jenkins L. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in . JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14. PMID: 31501807; PMCID: PMC6732782.
Copy Download .nbib Format: NLM
Share it on

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in .

JCO precision oncology

B A Carneiro, K A Collier, R J Nagy, S Pamarthy, V Sagar, S Fairclough, J Odegaard, R B Lanman, R Costa, T Taxter, T M Kuzel, A Fan, Y K Chae, M Cristofanilli, M H Hussain, S A Abdulkadir, F J Giles, Crawford, Jenkins

Affiliations

  1. Developmental Therapeutics Program, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
  2. The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  3. Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.
  4. Guardant Health, Inc., Redwood City, CA.
  5. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.
  6. Rush University Medical Center, Division of Hematology/Oncology, Chicago, IL.
  7. Stanford University School of Medicine, Palo Alto, CA.

PMID: 31501807 PMCID: PMC6732782 DOI: 10.1200/PO.17.00176

Abstract

PARP1/2 inhibitors are effective against BRCA2-deficient tumors. The PARP inhibitor (PARPi) olaparib received FDA breakthrough designation for treatment of metastatic castration-resistant prostate cancers (CRPC) carrying mutations in

References

  1. Cancer Res. 2003 May 15;63(10):2688-94 - PubMed
  2. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
  3. Nature. 2005 Apr 14;434(7035):917-21 - PubMed
  4. Cold Spring Harb Symp Quant Biol. 2005;70:139-48 - PubMed
  5. Nature. 2008 Feb 28;451(7182):1116-20 - PubMed
  6. Nature. 2008 Feb 28;451(7182):1111-5 - PubMed
  7. Cancer Res. 2009 Aug 15;69(16):6381-6 - PubMed
  8. Cancer Sci. 2011 Apr;102(4):663-9 - PubMed
  9. J Clin Oncol. 2011 Aug 1;29(22):3008-15 - PubMed
  10. J Pathol. 2013 Feb;229(3):422-9 - PubMed
  11. Clin Cancer Res. 2014 Feb 1;20(3):540-7 - PubMed
  12. Ann Oncol. 2014 Sep;25(9):1729-35 - PubMed
  13. PLoS One. 2015 Oct 16;10(10):e0140712 - PubMed
  14. Am J Surg Pathol. 2016 Feb;40(2):244-52 - PubMed
  15. N Engl J Med. 2015 Oct 29;373(18):1697-708 - PubMed
  16. Cancer Discov. 2016 Feb;6(2):147-153 - PubMed
  17. N Engl J Med. 2016 Nov 3;375(18):1804-5 - PubMed
  18. Science. 2017 Mar 17;355(6330):1152-1158 - PubMed
  19. J Clin Oncol. 2017 Apr 20;35(12):1274-1280 - PubMed
  20. Cancer Discov. 2017 Sep;7(9):1006-1017 - PubMed
  21. Cancer Discov. 2017 Sep;7(9):999-1005 - PubMed
  22. Nature. 1980 Feb 7;283(5747):593-6 - PubMed
  23. Br J Cancer. 1995 Nov;72(5):1241-4 - PubMed
  24. Cancer Res. 1995 Nov 1;55(21):4830-2 - PubMed
  25. Oncogene. 1995 Apr 20;10(8):1673-5 - PubMed
  26. Cancer Res. 1994 Dec 1;54(23):6069-72 - PubMed
  27. Am J Hum Genet. 1994 Nov;55(5):870-5 - PubMed
  28. Nature. 1995 Dec 21-28;378(6559):789-92 - PubMed

Publication Types

Grant support